| Name | Title | Contact Details |
|---|
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.
NeuroVasc Technologies is a developer of mechanical thrombectomy solutions for revascularization of the brain.
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
Sustainable Bioproducts has developed a breakthrough protein production platform for a variety of consumer and industrial applications.
ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.